Allogeneic RPE cell suspension manufactured at scale demonstrating preclinical safety and efficacy led to IND approval.
Lalitha Soundararajan, Harshini Surendran, Niharika Patlolla...
https://pubmed.ncbi.nlm.nih.gov/40253438/Actively Recruiting
Led by Eyestem Research Pvt. Ltd. · Updated on 2024-09-24
54
Participants Needed
3
Research Sites
295 weeks
Total Duration
Researchers are evaluating the safety and potential effectiveness of a new stem cell treatment called Eyecyte-RPE for people aged 50 and older with Geographic Atrophy GA caused by dry Age-related Macular Degeneration d-AMD. GA is a late stage of dry AMD that leads to progressive and irreversible vision loss. This trial is a Phase 12a study conducted in India, aiming to address the unmet need for treatments that can restore damaged retinal cells and improve vision quality. Participants will receive a single subretinal injection of Eyecyte-RPE, which contains retinal pigment epithelial cells derived from stem cells. There are three dose levels 100,000 cells, 200,000 cells, or 300,000 cells, depending on group assignment. After the injection, participants will be closely monitored for safety and potential benefits. The study uses advanced imaging tools like Fundus Autofluorescence, Optical Coherence Tomography, and other vision assessments to track changes. During the study, participants will attend scheduled visits for eye exams, imaging tests, vision tests, and quality of life questionnaires up to 12 months after treatment. Researchers will focus on measuring changes in the GA area, visual acuity, retinal sensitivity, and overall visual function. Safety monitoring includes checks for any adverse effects or complications related to the injection or immunosuppression therapy. The total participation duration is about one year, ensuring thorough follow-up.
CONDITIONS
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
D
Dr Jogin Desai, MBBS
D
Dr Rajani Battu, MBBS,MS,DNB,FRCS(Edin),PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Eyestem Research Pvt. Ltd.
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants receive a single-dose subretinal injection of Eyecyte-RPE™ to replace damaged retinal pigment epithelial cells in the eye affected by Geographic Atrophy.
1 baseline visit and multiple follow-up visits over 12 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Lalitha Soundararajan, Harshini Surendran, Niharika Patlolla...
https://pubmed.ncbi.nlm.nih.gov/40253438/Eyestem Research Pvt. Ltd.
Lead Sponsor